ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0063

Implementability of a SLE Medication Adherence Intervention
Abstract Number: 1269

Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Abstract Number: 1780

Improved Overall Survival in Patients with Lung Cancer and Autoimmune Rheumatic Diseases
Abstract Number: 0711

Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study
Abstract Number: 2113

Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
Abstract Number: 1162

Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment
Abstract Number: 0365

Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
Abstract Number: 1352

Improving Completion Rates of Routine Mental Health Screening for Depression and Anxiety in Paediatric Lupus Outpatient Clinic to Enhance Patient Mental Health Care
Abstract Number: 0346

Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
Abstract Number: 0730

Improving Mental Health Services in Children and Adolescents with Systemic Lupus Erythematosus by Establishing a Mental Health Care Navigator
Abstract Number: 1306

Improving Osteoporosis Screening in Individuals of Color
Abstract Number: 1277

Improving Patient Appropriate Osteoporosis Screening with Dual Energy X-ray Absorptiometry Scans in an Academic Internal Medicine Practice
Abstract Number: 1274

Improving Pneumococcal Vaccination Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse Driven Protocol
Abstract Number: 1755

Improving Quality of Life Through Connection: A Scoping Review of Peer Coaching Interventions in the Field of Rheumatology
Abstract Number: 1246

Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].